End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
21.71 CNY | +3.88% | +9.92% | -25.09% |
Apr. 30 | Pharmaron Beijing's Profit Rises 17% in 2023 | MT |
Apr. 29 | Nomura Adjusts Pharmaron’s Price Target to 31.41 Yuan From 36.68 Yuan, Keeps at Buy | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The group's high margin levels account for strong profits.
Weaknesses
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-25.09% | 4.7B | B+ | ||
+17.96% | 47.02B | B- | ||
+48.77% | 41.86B | A | ||
+1.17% | 41.76B | B | ||
-4.27% | 28.8B | C | ||
+11.42% | 26.05B | B- | ||
-21.39% | 19.15B | B | ||
+4.86% | 12.55B | B+ | ||
+27.29% | 12.34B | C+ | ||
-3.50% | 11.82B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 300759 Stock
- Ratings Pharmaron Beijing Co., Ltd.